<DOC>
	<DOC>NCT00212888</DOC>
	<brief_summary>The purpose of this study is to determine if vaccination before a structured treatment interruption (STI) is associated with an improvement in immune function, resulting in a delayed and reduced rebound in the amount of HIV virus in the blood.</brief_summary>
	<brief_title>Combination Vaccination Before HIV Treatment Interruption</brief_title>
	<detailed_description>Volunteers will be randomly assigned to receive the vaccines or matching placebos before interrupting their antiretroviral therapy at week 24. Dosage: Remune(TM) 1 ml i.m.* at weeks 0, 12, and 20; ALVAC 1 ml i.m.* at weeks 8,12, 16, and 20. * i.m.: injected in a muscle</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Documented HIV infection (by serology) HIV RNA level below 50 copies/ml for at least two years Receiving at least 2 antiretroviral agents including at least 1 protease inhibitor or 1 nonnucleoside reverse transcriptase inhibitor at time of screening Have CD4 counts above 500 cells/ul Have CD4/CD8 ratio above 0.5 Have never had a CD4 count below 250 No previous AIDSdefining opportunistic infection No previous cancer chemotherapy or other system immunosuppressive therapy (excluding brief courses [&lt;= 1 month] of prednisone or its equivalent) Able to provide informed consent Hepatitis B surface antigen positive Hepatitis C antibody positive AST, ALT, ALP, creatinine, urea above three times the normal upper limit Blood abnormalities (hemoglobin lower than 100, white blood cell count [WBC] lower than 1500 or platelets lower than 100) Allergies to components of Remuneâ„¢ or ALVAC Contraindications to vaccine components Pregnancy or breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccination</keyword>
</DOC>